1030 Sync Street
About Syneos Health
Why Syneos Health? Join a game-changing global company that is reinventing the way therapies are developed and commercialized. Created through the merger of two industry leading companies - INC Research and inVentiv Health - we bring together more than 21,000 clinical and commercial minds to create better, smarter, faster ways to get biopharmaceutical therapies to patients. Teaming with some of the most talented professionals in the industry, you'll gain exposure and work in a dynamic environment where you'll be supported with comprehensive resources including emerging technologies, data, science and knowledge sharing. Grow your career with a global company committed to shortening the distance from lab to life.
Every aspect of Syneos Health fuels our Biopharmaceutical Acceleration Model -- and unlike traditional CROs and commercialization businesses, here, clinical and commercial are working together to accelerate customer success.
177 articles with Syneos Health
GAAP revenue of $1,163.4 million for the three months ended March 31, 2020, representing growth of 4.0%, 3.8% on an adjusted basis, and 4.4% on a constant currency adjusted basis compared to the same period in 2019.
Company Expects Aggregate First Quarter Results to Be in Line With Previously Issued Guidance Range
Syneos Health Responds to COVID-19 Public Health Challenge by Joining Call to Action to Activate Clinically-Qualified Healthcare Professionals
Syneos Health, the only fully integrated biopharmaceutical solutions organization, announced a volunteer program to enable clinically-qualified employees to address the UK government’s call for volunteers to support COVID-19 testing.
Syneos Health Launches Ventilator Initiative to Raise Awareness of Bridging Option to Address Ventilator Shortage for COVID-19 Patients
Syneos Health (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the launch of a Ventilator Initiative.
Syneos Health (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization and a Contract Commercial Organization, today reported financial results for the three and twelve months ended December 31, 2019.
Syneos Health Schedules Fourth Quarter and Year End 2019 Earnings Call for Thursday, February 20, 2020
Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and year end 2019 financial results on Thursday, February 20, 2020,
Syneos Health Announces Strategic Collaboration and Investment in Indegene Omnipresence and the Company’s Next-Generation CRM and Omnichannel Engagement SaaS Platform
Omnipresence Platform Provides Biopharmaceutical Companies Advanced Analytics, AI and Cloud Innovations Powered by Microsoft
Syneos Health® announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 15, 2020, at 8:00 a.m. PST.
Syneos Health Insights Hub Releases 2020 Health Trends, Identifying Critical Shifts Impacting Drug Development and Commercialization
eBook Provides Blueprint for Successfully Navigating Dynamic Healthcare Environment
Syneos Health Releases Report Identifying Barriers to Payer Use of RWE in Rare Disease and Recommendations for Advancing Payer Engagement
Company Launches Syneos Health Insights Hub to Provide Biopharma Leaders with Actionable Insights Informed by Dynamic Research
With Connaughton’s appointment, the Company’s Board has been expanded from 10 to 11 directors, 10 of whom are independent.
Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com.
Medidata NEXT London 2019: Blending the Best of Clinical Development, AI-Enabled Platform Demonstrations and Regulatory Compliance for Leaders in Life Sciences
Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ahead of regulatory and market developments
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Syneos Health, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Syneos Health, Inc. of the April 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SYNEOS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Syneos Health, Inc. - SYNH
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 30, 2019 to file lead plaintiff applications in a securities class action lawsuit against Syneos Health, Inc.
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Syneos Health, Inc. - SYNH
The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Syneos Health, Inc. on behalf of purchasers of Syneos securities between May 10, 2017 through February 27, 2019, inclusive.
SYNH LAWSUIT NOTICE: Rosen Law Firm Files Securities Class Action Lawsuit Against Syneos Health, Inc. - SYNH
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Syneos Health, Inc. from May 10, 2017 through February 27, 2019, inclusive.
Syneos (SYNH) Investigation: Bernstein Liebhard LLP Announces First Investigation Of Syneos Health, Inc. - SYNH
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Syneos Health, Inc. resulting from allegations that Syneos and/or its executives may have issued materially misleading business information to the investing public.
SYNH INVESTIGATIVE ALERT: Hagens Berman Alerts Syneos Health (SYNH) Investors to Investigation of Possible Improper Accounting
Hagens Berman Sobol Shapiro LLP alerts investors in Syneos Health, Inc. to the firm's investigation of possible improper accounting and possible violations of securities laws.
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.